Pelage announced positive Phase 2a results in June 2025 (78 men and women, 4 weeks of daily dosing, 12-week follow-up) and a $120M Series B (Oct 2025, co-led by ARCH Venture Partners and GV/Google Ventures) to fund Phase 3.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Phase 2
How it works
Topical small molecule designed to reactivate dormant hair follicle stem cells and push them into the growth (anagen) phase, a regenerative rather than hormone-blocking approach.
Results so far
Met primary safety/efficacy endpoints with no systemic absorption; 31% of men showed >20% increase in hair density, including new growth in previously bald areas (press-release figures).
What's next
Phase 3 studies planned to begin in 2026.
In India
No India-specific development identified.
Sources
- Company announcement ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
- Company announcement ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.